CAV Regimen Bridging to HSCT for R/R AL
Acute Leukemia, Relapsed, Acute Leukemia Refractory
About this trial
This is an interventional treatment trial for Acute Leukemia, Relapsed focused on measuring CAV regimen, HSCT
Eligibility Criteria
Inclusion Criteria:
Patients with AL must meet one of the following criteria :A or B. A: relapsed AL disease was defined as follows: (1) Reappearance of leukemic blasts in the peripheral blood after CR; or (2) detection of >5% blasts in the bone marrow (BM) not attributable to another cause(e.g. regeneration after consolidation therapy); or (3) extramedullary relapse.
B: refractory AL disease was defined as follows: (1): failure to attained CR following exposure to at least 2 courses of standard or intensive induction therapy; or (2) bone marrow leukemia cell decline index (BMCDI)<50% and >15% blast existence after one course of standard or intensive induction therapy.
- patients without serious disease of heart or liver or lung or kidneys.
- sign informed consent voluntarily.
- Patients aged between 18 and 65 years old, male or female is permitted.
- ECOG performance status score less than 1.
- The expected survival is longer than 3 months.
Exclusion Criteria:
- With other malignant tumors.
- Patients received the treatment of cladribine or venetoclax.
- Patients received cardiac angioplasty or stent implantation.
- Active infections that are not under clinical control (bacteria or fungus or virus is included).
- Liver functions abnormalities (total bilirubin>1.5 times the upper limit of the normal range, ALT/AST>2.5 times the upper limit of the normal range or patients with liver involvement whose ALT/AST>1.5 times the upper limit of the normal range), or renal anomalies (serum creatinine>1.5 times the upper limit of normal value).
- Pregnant or nursing women.
- Patients with mental disorders or other conditions whereby informed consent cannot be obtained and where the requirements of the study treatment and procedures cannot be met.
- Patients participated in any other clinical trials 3 months prior to signing the informed consent.
- Patients not suitable for the study according to the investigator's assessment.
Sites / Locations
- The First Affiliated Hospital of Soochow UniversityRecruiting
Arms of the Study
Arm 1
Experimental
CAV Regimen Bridging to HSCT